MX2021007271A - Nuevas moleculas de acido nucleico conjugado y sus usos. - Google Patents

Nuevas moleculas de acido nucleico conjugado y sus usos.

Info

Publication number
MX2021007271A
MX2021007271A MX2021007271A MX2021007271A MX2021007271A MX 2021007271 A MX2021007271 A MX 2021007271A MX 2021007271 A MX2021007271 A MX 2021007271A MX 2021007271 A MX2021007271 A MX 2021007271A MX 2021007271 A MX2021007271 A MX 2021007271A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid molecules
conjugated nucleic
new conjugated
new
Prior art date
Application number
MX2021007271A
Other languages
English (en)
Inventor
Brian Sproat
Christelle Zandanel
Françoise Bono
Alexandre Simon
Original Assignee
Onxeo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo filed Critical Onxeo
Publication of MX2021007271A publication Critical patent/MX2021007271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Abstract

La presente invención se refiere a nuevas moléculas de ácido nucleico de interés terapéutico, en particular para uso en el tratamiento del cáncer.
MX2021007271A 2018-12-21 2019-12-20 Nuevas moleculas de acido nucleico conjugado y sus usos. MX2021007271A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18306829 2018-12-21
EP18306826 2018-12-21
EP19202834 2019-10-11
EP19202837 2019-10-11
PCT/EP2019/086672 WO2020127965A1 (en) 2018-12-21 2019-12-20 New conjugated nucleic acid molecules and their uses

Publications (1)

Publication Number Publication Date
MX2021007271A true MX2021007271A (es) 2021-07-15

Family

ID=69005729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007271A MX2021007271A (es) 2018-12-21 2019-12-20 Nuevas moleculas de acido nucleico conjugado y sus usos.

Country Status (11)

Country Link
US (1) US20220054524A1 (es)
EP (1) EP3898974A1 (es)
JP (2) JP7450622B2 (es)
KR (1) KR20210109564A (es)
CN (1) CN113166762A (es)
AU (1) AU2019408408A1 (es)
BR (1) BR112021012066A2 (es)
CA (1) CA3118182A1 (es)
IL (1) IL282838A (es)
MX (1) MX2021007271A (es)
WO (1) WO2020127965A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765613A1 (en) * 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
NZ532610A (en) * 2001-10-29 2008-03-28 Univ Mcgill Acyclic linker-containing oligonucleotides and uses thereof
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
KR101325023B1 (ko) 2003-07-02 2013-11-04 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
SI1648507T1 (sl) 2003-07-24 2017-07-31 Innate Pharma S.A. Metode in sestavki za povečanje učinkovitosti terapevtskih protiteles z uporabo potenciranja spojin nk celice
EP1526177A1 (en) 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality
US7476729B2 (en) 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
CN104829720B (zh) 2005-01-06 2019-01-01 诺和诺德公司 Kir结合剂和使用其的方法
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2623109C (en) 2005-10-14 2019-02-19 Innate Pharma Nk cell-depleting antibodies for treating immunoproliferative disorders
CN102614528B (zh) 2006-08-18 2014-02-26 箭头研究公司 用于体内递送多核苷酸的多缀合物
EP2109460B1 (en) 2007-01-11 2016-05-18 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
EP1944369A1 (en) 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
CN105001333B (zh) 2007-12-14 2019-05-17 诺沃—诺迪斯克有限公司 抗人nkg2d抗体及其用途
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2274425A2 (en) 2008-04-11 2011-01-19 Alnylam Pharmaceuticals Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
ES2550384T3 (es) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc para la inmunoterapia
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
JP5920929B2 (ja) 2010-03-11 2016-05-18 ユセベ ファルマ ソシエテ アノニム Ｐｄ−１抗体
TR201807750T4 (tr) 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
PT3135301T (pt) * 2010-06-22 2018-07-16 Inst Curie Sistema de administração otimizado in vivo com agentes endossomolíticos para conjugados de ácidos nucleicos
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
TWI664191B (zh) 2010-11-22 2019-07-01 天賜製藥公司 Ｎｋ細胞調節治療及治療血液惡性疾病之方法
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
EP2714741B1 (en) 2011-05-25 2019-10-30 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory disorders
EP2527440A1 (en) * 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
EA038920B1 (ru) 2012-10-02 2021-11-10 Бристол-Майерс Сквибб Компани Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
EP2903641A2 (en) 2012-10-04 2015-08-12 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
WO2014170441A1 (en) * 2013-04-19 2014-10-23 Dna Therapeutics Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
RS59480B1 (sr) 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena
CN113637692A (zh) 2014-01-15 2021-11-12 卡德门企业有限公司 免疫调节剂
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2902369T3 (es) 2014-01-28 2022-03-28 Bristol Myers Squibb Co Anticuerpos anti-LAG-3 para tratar neoplasias malignas hemáticas
EP3149042B1 (en) 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
RS59664B1 (sr) 2014-11-06 2020-01-31 Hoffmann La Roche Anti-tim3 antitela i postupci upotrebe
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US9873741B2 (en) 2015-03-06 2018-01-23 Sorrento Therapeutics, Inc. Antibody therapeutics that bind TIM3
WO2016158809A1 (ja) * 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
KR101896567B1 (ko) * 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
EP3373952A4 (en) 2015-11-10 2019-05-22 Fred Hutchinson Cancer Research Center NKG2D decoys
US20180327499A1 (en) 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CN114853907A (zh) 2015-11-13 2022-08-05 达纳-法伯癌症研究所有限公司 用于癌症免疫疗法的nkg2d-ig融合蛋白
EP3423068A1 (en) * 2016-03-01 2019-01-09 Onxeo Treatment of cancer by systemic administration of dbait molecules
JP2019517993A (ja) 2016-03-15 2019-06-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｍｉｃａ抗体
WO2017186882A1 (en) * 2016-04-29 2017-11-02 Onxeo A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
KR20190038919A (ko) 2016-08-19 2019-04-09 얀센 바이오테크 인코포레이티드 항-nkg2d 항체로 크론병을 치료하는 방법
US11066471B2 (en) 2016-10-19 2021-07-20 Novelogics Biotechnology Inc. Antibodies to MICA and MICB proteins
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule

Also Published As

Publication number Publication date
JP7450622B2 (ja) 2024-03-15
CA3118182A1 (en) 2020-06-25
KR20210109564A (ko) 2021-09-06
JP2022514259A (ja) 2022-02-10
EP3898974A1 (en) 2021-10-27
JP2024054419A (ja) 2024-04-16
WO2020127965A1 (en) 2020-06-25
US20220054524A1 (en) 2022-02-24
IL282838A (en) 2021-06-30
BR112021012066A2 (pt) 2021-11-03
AU2019408408A1 (en) 2021-06-03
CN113166762A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2019001920A (es) Arn la terapia contra el cancer.
PH12019501959A1 (en) Therapeutic rna
MX2019012233A (es) Anticuerpos anti-sirpa.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MD4733B1 (ro) Anticorpi anti-TIGIT
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
WO2015009726A3 (en) Medical uses of cd38 agonists
AU2018278311A1 (en) IRE1 small molecule inhibitors
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2023002076A (es) Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
WO2015169811A3 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents